#### MACKAY MARTIN Form 3 May 15, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

#### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

#### **OMB APPROVAL**

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> MACKAY MARTIN	2. Date of Event Requiring Statement (Month/Day/Year) 05/13/2013	3. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]			
(Last) (First) (Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O ALEXION PHARMACEUTICALS,		(Check all applicable)			
INC, 352 KNOTTER DRIVE (Street)		Director 10% Owner X Officer Other	6. Individual or Joint/Group		

#### (Street)

# CHESHIRE, CTÂ 06410

(City)	(State)	(Zip)

1. Title of Security (Instr. 4)

## Table I - Non-Derivative Securities Beneficially Owned

Ownership

Direct (D) or Indirect (I) (Instr. 5)

Form:

(give title below) (specify below)

3.

EVP & Global Head of R&D

2. Amount of Securities Beneficially Owned (Instr. 4)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reporting Person

Person

Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting

\_ Form filed by More than One

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	(Month/Day/Year) Deriv		3. Title and Securities U Derivative S (Instr. 4)	Inderlying	4. Conversion or Exercise Price of	5.6. Nature of IndirectOwnershipBeneficial OwnershipForm of(Instr. 5)Derivative	
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

# Edgar Filing: MACKAY MARTIN - Form 3

Shares	or Indirect
	(I)
	(Instr. 5)

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships				
		Director	10% Owner	Officer	Other	
MACKAY MARTIN C/O ALEXION PHARMACEUTICALS, INC 352 KNOTTER DRIVE CHESHIRE, CT 06410		Â	Â	EVP & Global Head of R&D	Â	
Signatures						
/s/ Martin MacKay	05/15/2013					
<u>**</u> Signature of Reporting Person	Date					
Explanation of Responses:						

### No securities are beneficially owned

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.